Guoji Yanke Zazhi (Jul 2024)

Therapeutic effect of ultrasonic cycloplasty combined with anti-vascular endothelial growth factor plus panretinal photocoagulation in the treatment of advanced neovascular glaucoma

  • Chen Tianyi,
  • Chen Yuanzhi,
  • Guo Denghua,
  • Yang Yang,
  • Wang Tong,
  • Zhang Qinghui,
  • Yao Hongbao,
  • Song Changrui,
  • Yang Xiao

DOI
https://doi.org/10.3980/j.issn.1672-5123.2024.7.06
Journal volume & issue
Vol. 24, no. 7
pp. 1038 – 1042

Abstract

Read online

AIM: To evaluate the safety and efficacy of ultrasonic cycloplasty(UCP)combined with anti-vascular endothelial growth factor(VEGF)+ panretinal photocoagulation(PRP)in the treatment of advanced neovascular glaucoma(NVG).METHODS: Retrospective study. A total of 45 patients(45 eyes)with advanced NVG who received surgery in our hospital from August 2020 to September 2022 were collected and divided into UCP+ anti-VEGF +PRP group(16 patients, 16 eyes), transscleral cyclophotocoagulation(TCP)+anti-VEGF+PRP group(20 patients, 20 eyes), UCP alone group(9 patients, 9 eyes). The intraocular pressure, pain scores, postoperative medication, effective rate, total success rate and the incidence of complications of the patients in the three groups were compared before surgery and at 1 d, 1 wk, 1 and 3 mo after surgery.RESULTS: There was no significant difference in preoperative intraocular pressure, pain scores and preoperative medication of patients in the three groups(all P>0.05). While there were statistical significance in the intraocular pressure and pain scores at 1 d, 1 wk, 1 and 3 mo after surgery(all P0.05).CONCLUSION: UCP combined with anti-VEGF +PRP and TCP combined with anti-VEGF +PRP showed comparable efficacy in reducing intraocular pressure in advanced NVG. UCP combined with anti-VEGF+PRP was more effective in relieving pain and with no serious complications in advanced NVG. UCP alone can effectively control intraocular pressure and alleviate the pain of patients in the early postoperative period, but long-term control still requires anti-VEGF+PRP.

Keywords